Orchard Therapeutics plc, of London, closed its IPO of about 16 million American depositary shares (ADSs), each representing an ordinary share at $14 each. The gross proceeds from the offering were $225.5 million, and that includes the partial exercise by the underwriters of their option to purchase up to about 1.8 million ADSs from Orchard. J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book-running managers for the offering, and Wedbush Pacgrow is serving as co-manager.